Medy-Tox Inc. (KOSDAQ:086900)

Ligand Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	237,990	228,622	221,121	195,096	184,870	140,828
Other Revenue	-	-	-	-0	-0	-
Revenue	237,990	228,622	221,121	195,096	184,870	140,828
Revenue Growth (YoY)	2.13%	3.39%	13.34%	5.53%	31.27%	-31.60%
Cost of Revenue	94,457	90,038	87,625	69,048	79,397	66,928
Gross Profit	143,534	138,584	133,496	126,048	105,473	73,900
Selling, General & Admin	76,913	78,370	86,605	47,679	41,938	59,544
Research & Development	29,821	29,821	25,133	23,324	23,267	32,544
Other Operating Expenses	1,346	1,346	1,322	1,242	1,216	1,403
Operating Expenses	116,779	118,236	116,173	79,383	72,335	110,969
Operating Income	26,755	20,349	17,322	46,665	33,138	-37,070
Interest Expense	-1,727	-1,727	-2,333	-2,314	-4,781	-4,176
Interest & Investment Income	925.15	925.15	896.43	610.76	957.22	340.02
Earnings From Equity Investments	6,179	5,877	1,363	5,129	-1,456	-2,432
Currency Exchange Gain (Loss)	4,387	4,387	475.22	3,425	2,111	-376.81
Other Non Operating Income (Expenses)	-5,227	-4,138	-605.87	-715.84	108,431	6,967
EBT Excluding Unusual Items	31,292	25,673	17,118	52,800	138,400	-36,748
Impairment of Goodwill	-	-	-	-	-	-711.12
Gain (Loss) on Sale of Investments	126.49	126.49	-593.36	-3,044	2,666	-1,067
Gain (Loss) on Sale of Assets	323.58	323.58	-671.97	-230.42	131.48	58.63
Asset Writedown	-8,624	-8,624	-	-	-12,932	-3,671
Pretax Income	23,118	17,499	15,853	49,526	128,265	-42,139
Income Tax Expense	2,239	1,425	6,163	12,930	35,003	-12,100
Earnings From Continuing Operations	20,879	16,074	9,690	36,596	93,263	-30,039
Minority Interest in Earnings	1,351	881.22	65.28	414.16	891.27	462.11
Net Income	22,230	16,955	9,755	37,010	94,154	-29,577
Preferred Dividends & Other Adjustments	975	975	975	975.33	974.73	0.7
Net Income to Common	21,255	15,980	8,780	36,035	93,179	-29,577
Net Income Growth	715.60%	73.81%	-73.64%	-60.69%	-	-
Shares Outstanding (Basic)	8	7	7	7	6	6
Shares Outstanding (Diluted)	8	7	7	7	6	6
Shares Change (YoY)	36.62%	0.40%	2.02%	2.28%	0.04%	-0.82%
EPS (Basic)	2677.00	2376.57	1311.06	5491.68	14587.59	-4609.95
EPS (Diluted)	2677.00	2376.57	1311.00	5489.34	14517.37	-4610.30
EPS Growth	788.90%	81.28%	-76.12%	-62.19%	-	-
Free Cash Flow	30,491	27,830	5,862	16,304	2,452	-13,217
Free Cash Flow Per Share	3840.26	4138.95	875.31	2483.66	382.01	-2059.99
Dividend Per Share	1100.000	1100.000	-	-	-	-
Gross Margin	60.31%	60.62%	60.37%	64.61%	57.05%	52.48%
Operating Margin	11.24%	8.90%	7.83%	23.92%	17.93%	-26.32%
Profit Margin	8.93%	6.99%	3.97%	18.47%	50.40%	-21.00%
Free Cash Flow Margin	12.81%	12.17%	2.65%	8.36%	1.33%	-9.38%
EBITDA	46,848	40,307	32,698	61,766	51,394	-18,472
EBITDA Margin	19.68%	17.63%	14.79%	31.66%	27.80%	-13.12%
D&A For EBITDA	20,093	19,959	15,376	15,101	18,256	18,597
EBIT	26,755	20,349	17,322	46,665	33,138	-37,070
EBIT Margin	11.24%	8.90%	7.83%	23.92%	17.93%	-26.32%
Effective Tax Rate	9.69%	8.15%	38.88%	26.11%	27.29%	-
Advertising Expenses	-	7,146	5,976	3,351	2,031	3,839

Source: S&P Global Market Intelligence. Standard template. Financial Sources.